Management of splenomegaly in patients with myelofibrosis in the era of JAK inhibitors: a comprehensive review.

Al-Asa'd Y, Qasem N, Alshurafa A, Al-Farsi K, Yassin MA

Open source

DOI
10.3389/fonc.2026.1851781
Published
2026
Container
Frontiers in oncology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fonc.2026.1851781,
  title = {Management of splenomegaly in patients with myelofibrosis in the era of JAK inhibitors: a comprehensive review.},
  author = {Al-Asa'd Y and Qasem N and Alshurafa A and Al-Farsi K and Yassin MA},
  year = {2026},
  journal = {Frontiers in oncology},
  doi = {10.3389/fonc.2026.1851781},
  url = {https://doi.org/10.3389/fonc.2026.1851781}
}

RIS

TY  - JOUR
TI  - Management of splenomegaly in patients with myelofibrosis in the era of JAK inhibitors: a comprehensive review.
AU  - Al-Asa'd Y
AU  - Qasem N
AU  - Alshurafa A
AU  - Al-Farsi K
AU  - Yassin MA
PY  - 2026
JO  - Frontiers in oncology
DO  - 10.3389/fonc.2026.1851781
UR  - https://doi.org/10.3389/fonc.2026.1851781
ER  - 

APA

Y, A., N, Q., A, A., K, A., & MA, Y. (2026). Management of splenomegaly in patients with myelofibrosis in the era of JAK inhibitors: a comprehensive review.. Frontiers in oncology. https://doi.org/10.3389/fonc.2026.1851781

Source records